Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis® in Turkey
Details : Trabectedin is currently provided by Janssen to patients in Turkey for the treatment of Soft Tissue Sarcoma and, through this license, Onko will also pursue regulatory approval for the indication of relapsed ovarian cancer.
Brand Name : Yondelis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?